Hualan Biological Engineering Inc. (SHE: 002007)
China
· Delayed Price · Currency is CNY 17.15
-0.04 (-0.23%)
Nov 15, 2024, 12:38 PM CST
Hualan Biological Engineering Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 1,338 | 1,482 | 1,076 | 1,299 | 1,613 | 1,283 | Upgrade
|
| Depreciation & Amortization | 259.25 | 259.25 | 272.82 | 196.45 | 181.66 | 160.9 | Upgrade
|
| Other Amortization | 14.54 | 14.54 | 14.77 | 10.04 | 5.12 | 0.23 | Upgrade
|
| Loss (Gain) From Sale of Assets | -44.44 | -44.44 | -47.67 | -0.42 | 0.26 | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | 9.71 | 9.71 | 1.19 | 3.23 | 0.62 | 1.67 | Upgrade
|
| Loss (Gain) From Sale of Investments | -209.59 | -209.59 | -144.05 | -100.22 | -110.73 | -171.04 | Upgrade
|
| Provision & Write-off of Bad Debts | 13.92 | 13.92 | 32.83 | 11.29 | 42.34 | 6.35 | Upgrade
|
| Other Operating Activities | 295.09 | 384.37 | 358.97 | 309.88 | 274.52 | 151.94 | Upgrade
|
| Change in Accounts Receivable | -302.66 | -302.66 | -538.11 | 162.97 | -1,247 | -68.08 | Upgrade
|
| Change in Inventory | -316.45 | -316.45 | -245.23 | -317.36 | -48.7 | -5.45 | Upgrade
|
| Change in Accounts Payable | 7.97 | 7.97 | 190.01 | -137.32 | 673.69 | 11.73 | Upgrade
|
| Change in Other Net Operating Assets | 34.82 | 34.82 | 6.36 | 4.14 | 22.44 | 2.06 | Upgrade
|
| Operating Cash Flow | 1,113 | 1,346 | 957.31 | 1,432 | 1,325 | 1,363 | Upgrade
|
| Operating Cash Flow Growth | -27.66% | 40.59% | -33.17% | 8.09% | -2.75% | 5.42% | Upgrade
|
| Capital Expenditures | -676.88 | -753.41 | -393.95 | -811.35 | -621.44 | -272.95 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.55 | 204.11 | 50.32 | 0.91 | 0.11 | 0.13 | Upgrade
|
| Divestitures | 1.55 | - | - | - | 0.02 | - | Upgrade
|
| Investment in Securities | 74.53 | -536.92 | -2,175 | -1,075 | -223.86 | -572.14 | Upgrade
|
| Other Investing Activities | 167.41 | 87.94 | 68.89 | 126.6 | 105.79 | - | Upgrade
|
| Investing Cash Flow | -431.84 | -998.28 | -2,450 | -1,759 | -739.39 | -844.97 | Upgrade
|
| Long-Term Debt Issued | - | 700 | 1,100 | 1,300 | 450 | - | Upgrade
|
| Total Debt Issued | 400 | 700 | 1,100 | 1,300 | 450 | - | Upgrade
|
| Long-Term Debt Repaid | - | -600.38 | -1,001 | -700 | -50 | - | Upgrade
|
| Total Debt Repaid | -250.38 | -600.38 | -1,001 | -700 | -50 | - | Upgrade
|
| Net Debt Issued (Repaid) | 149.62 | 99.62 | 99.24 | 600 | 400 | - | Upgrade
|
| Issuance of Common Stock | 64.35 | 48.07 | 2,255 | - | 5.02 | 49.89 | Upgrade
|
| Common Dividends Paid | -473.77 | -563.64 | -399.47 | -564.11 | -571.5 | -390.65 | Upgrade
|
| Other Financing Activities | -223.8 | -39 | -36.57 | - | -59.72 | - | Upgrade
|
| Financing Cash Flow | -483.6 | -454.96 | 1,918 | 35.89 | -226.2 | -340.76 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.02 | 0.06 | 0.05 | -0.03 | 0 | -0 | Upgrade
|
| Net Cash Flow | 197.51 | -107.33 | 425.29 | -290.45 | 359.71 | 177.03 | Upgrade
|
| Free Cash Flow | 436.05 | 592.43 | 563.36 | 621.15 | 703.85 | 1,090 | Upgrade
|
| Free Cash Flow Growth | -46.00% | 5.16% | -9.30% | -11.75% | -35.42% | -1.76% | Upgrade
|
| Free Cash Flow Margin | 8.86% | 11.09% | 12.47% | 14.00% | 14.01% | 29.45% | Upgrade
|
| Free Cash Flow Per Share | 0.24 | 0.32 | 0.31 | 0.34 | 0.39 | 0.60 | Upgrade
|
| Cash Income Tax Paid | 502.61 | 503.9 | 457.29 | 564.96 | 468.02 | 417.61 | Upgrade
|
| Levered Free Cash Flow | -759.18 | -696.55 | -498.06 | 252 | 477.44 | 763.95 | Upgrade
|
| Unlevered Free Cash Flow | -749.64 | -688.32 | -479.15 | 265.58 | 480.54 | 768.38 | Upgrade
|
| Change in Net Working Capital | 1,323 | 1,376 | 1,167 | 124.01 | 351.65 | 18.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.